Communicating statistical concerns to the FDA
|
|
3
|
236
|
March 11, 2024
|
Is Lithium Equivalent to Lecanemab in Slowing cognitive decline in Alzheimer's Disease?
|
|
0
|
275
|
February 23, 2024
|
Prior design in a bayesian re-analysis of an RCT
|
|
1
|
140
|
February 19, 2024
|
Assessing correlation/surrogacy between 2 estimated treatment effects
|
|
9
|
358
|
February 17, 2024
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
34
|
2679
|
February 16, 2024
|
RCT: protocol deviation and implications for analysis
|
|
6
|
284
|
February 16, 2024
|
Time to pre-randomization monthly seizure count
|
|
1
|
130
|
February 8, 2024
|
ITT analysis population - RCT
|
|
6
|
711
|
February 3, 2024
|
Ranked analysis of ANCOVA
|
|
7
|
461
|
January 21, 2024
|
Bayesian Dynamic Borrowing with Robust Mixture Priors: Fair or not?
|
|
7
|
330
|
January 18, 2024
|
Language for communicating frequentist results about treatment effects
|
|
200
|
107847
|
January 9, 2024
|
Substituting treatment arm with drug exposure (continuous variable) in RCT
|
|
10
|
333
|
January 8, 2024
|
Encryption of dataset in REDCap
|
|
3
|
329
|
December 15, 2023
|
Mixed models modelling
|
|
14
|
1053
|
October 26, 2023
|
Summary Statistics vs Raw Data
|
|
9
|
8926
|
October 23, 2023
|
Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
555
|
September 4, 2023
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
563
|
August 29, 2023
|
Effect modification in series of n-of-1 trials (repeated crossover)
|
|
2
|
399
|
August 25, 2023
|
Individual response
|
|
234
|
33448
|
August 21, 2023
|
Data collected outside of guidelines/window
|
|
10
|
838
|
June 13, 2023
|
Different results in unconstrained partial proportional odds model
|
|
0
|
657
|
May 22, 2023
|
Attrition Sensitive Randomisation
|
|
1
|
820
|
April 25, 2023
|
Randomization in a diagnostic study - necessary?
|
|
3
|
865
|
March 16, 2023
|
Appropriate model for combined data from two RCTs
|
|
10
|
725
|
March 8, 2023
|
RCT with missing follow-up outcomes: ANCOVA + MI vs Mixed-Effects Modelling?
|
|
50
|
4907
|
March 7, 2023
|
FDA "Bad Habits"
|
|
7
|
1853
|
March 4, 2023
|
Resources for handling blocked randomization in the analysis of RCTs
|
|
10
|
1190
|
February 11, 2023
|
Toward Guidelines for RCT Measurements.. What are the characteristics of an acceptable measurement for RCT?
|
|
0
|
878
|
February 10, 2023
|
What is a fake measurement tool and how are they used in RCT
|
|
46
|
16169
|
January 23, 2023
|
Rescue analysis for % change from baseline as an outcome in RCT
|
|
16
|
1720
|
January 16, 2023
|